09-29-2008: Lab21 announced the expansion of its portfolio of genetic tests for inherited cardiac syndromes. Through its existing UK licence with PGxHealth™, a division of Clinical Data, Inc., Lab21 offers exclusive U.K. and Ireland access to the Familion® portfolio of tests for Long QT and Brugada Syndromes and has now added two new assays for Catecholaminergic Polymorphic Ventricular Tachycardia (CPVT) and Hypertrophic Cardiomyopathy (HCM) to its range of tests.
Berwyn Clarke, Lab21 Chief Scientific and Development Officer commented: “We are delighted to expand our relationship with PGxHealth, who we believe is the market leader in the development of advanced genetic tests for inherited cardiac conditions. The addition of CPVT and HCM to the Familion stable substantially assists UK cardiologists in the accurate diagnosis of cardiac disease. By enabling cardiologists to quickly identify a patient’s risk, the most appropriate monitoring, treatment or lifestyle options can be implemented, significantly improving patient health.”
Lab21 Limited has won the BioNow Biomedical Project of the Year Award for its MycAssay product line. The BioNow Biomedical Project of the Year Award recognises individuals or organisations who have demonstrated an innovative solution to a specific industry problem. Lab21’s MycAssay Aspergi ... more
Lab21 Limited has announced the completion of an evaluation of a commercial PCR test, its MycAssayTM Aspergillus assay, to detect invasive Aspergillosis (IA) in a mixed population of 158 patients with underlying haematological or critical illness. The prospective evaluation was performed by ... more
Lab21 Limited has announced that its Clinical Laboratory Division has extended its Clinical Pathology Accreditation (CPA) scope to include Molecular Biology and Virology in addition to Biochemistry.
The accreditation was awarded by Clinical Pathology Accreditation (UK), the quality assuranc ... more